Cargando…

Low-Cost Predictors for Liver Function and Clinical Outcomes after Sustained Virological Response in Patients with HCV-Related Cirrhosis and Thrombocytopenia

Background and Objectives: To find low-cost markers that can identify the hepatitis C virus cirrhotic patients that are at risk for long-term severe adverse liver effects (ascites, ascites or upper gastrointestinal bleeding, hepatocellular carcinoma), after treatment. There is established evidence f...

Descripción completa

Detalles Bibliográficos
Autores principales: Omer, Secil, Iftime, Adrian, Constantinescu, Ileana, Dina, Ion
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865508/
https://www.ncbi.nlm.nih.gov/pubmed/36676770
http://dx.doi.org/10.3390/medicina59010146
_version_ 1784875855611166720
author Omer, Secil
Iftime, Adrian
Constantinescu, Ileana
Dina, Ion
author_facet Omer, Secil
Iftime, Adrian
Constantinescu, Ileana
Dina, Ion
author_sort Omer, Secil
collection PubMed
description Background and Objectives: To find low-cost markers that can identify the hepatitis C virus cirrhotic patients that are at risk for long-term severe adverse liver effects (ascites, ascites or upper gastrointestinal bleeding, hepatocellular carcinoma), after treatment. There is established evidence for the benefits of treating hepatitis C virus cirrhotic patients, but there is still some need for clarification concerning the real impact on the long-term evolution after achieving sustained virological response; there is no general consensus in the literature about identifying the patients that do not improve post-treatment. Materials and Methods: Our retrospective analysis investigated the long-term (2 years) evolution of 46 patients with cirrhosis with thrombocytopenia, previously infected with VHC, treated and who obtained an SVR after DAA treatment. Results: Despite the overall improvement, 8.7% patients developed hepatocellular carcinoma and 6.5% patients ascites/upper GI bleeding. We found that FIB-4, MELD and AFP changes at 1 year were the most significant predictors for these outcomes. Additionally, a drop in leukocyte count after 1 year seemed to indicate a risk for hepatocellular carcinoma, but this was not consistent. Conclusions: It might be beneficial to intensify the surveillance for post-treatment adverse liver effects for the patients with these marker changes at 1 year.
format Online
Article
Text
id pubmed-9865508
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98655082023-01-22 Low-Cost Predictors for Liver Function and Clinical Outcomes after Sustained Virological Response in Patients with HCV-Related Cirrhosis and Thrombocytopenia Omer, Secil Iftime, Adrian Constantinescu, Ileana Dina, Ion Medicina (Kaunas) Article Background and Objectives: To find low-cost markers that can identify the hepatitis C virus cirrhotic patients that are at risk for long-term severe adverse liver effects (ascites, ascites or upper gastrointestinal bleeding, hepatocellular carcinoma), after treatment. There is established evidence for the benefits of treating hepatitis C virus cirrhotic patients, but there is still some need for clarification concerning the real impact on the long-term evolution after achieving sustained virological response; there is no general consensus in the literature about identifying the patients that do not improve post-treatment. Materials and Methods: Our retrospective analysis investigated the long-term (2 years) evolution of 46 patients with cirrhosis with thrombocytopenia, previously infected with VHC, treated and who obtained an SVR after DAA treatment. Results: Despite the overall improvement, 8.7% patients developed hepatocellular carcinoma and 6.5% patients ascites/upper GI bleeding. We found that FIB-4, MELD and AFP changes at 1 year were the most significant predictors for these outcomes. Additionally, a drop in leukocyte count after 1 year seemed to indicate a risk for hepatocellular carcinoma, but this was not consistent. Conclusions: It might be beneficial to intensify the surveillance for post-treatment adverse liver effects for the patients with these marker changes at 1 year. MDPI 2023-01-11 /pmc/articles/PMC9865508/ /pubmed/36676770 http://dx.doi.org/10.3390/medicina59010146 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Omer, Secil
Iftime, Adrian
Constantinescu, Ileana
Dina, Ion
Low-Cost Predictors for Liver Function and Clinical Outcomes after Sustained Virological Response in Patients with HCV-Related Cirrhosis and Thrombocytopenia
title Low-Cost Predictors for Liver Function and Clinical Outcomes after Sustained Virological Response in Patients with HCV-Related Cirrhosis and Thrombocytopenia
title_full Low-Cost Predictors for Liver Function and Clinical Outcomes after Sustained Virological Response in Patients with HCV-Related Cirrhosis and Thrombocytopenia
title_fullStr Low-Cost Predictors for Liver Function and Clinical Outcomes after Sustained Virological Response in Patients with HCV-Related Cirrhosis and Thrombocytopenia
title_full_unstemmed Low-Cost Predictors for Liver Function and Clinical Outcomes after Sustained Virological Response in Patients with HCV-Related Cirrhosis and Thrombocytopenia
title_short Low-Cost Predictors for Liver Function and Clinical Outcomes after Sustained Virological Response in Patients with HCV-Related Cirrhosis and Thrombocytopenia
title_sort low-cost predictors for liver function and clinical outcomes after sustained virological response in patients with hcv-related cirrhosis and thrombocytopenia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865508/
https://www.ncbi.nlm.nih.gov/pubmed/36676770
http://dx.doi.org/10.3390/medicina59010146
work_keys_str_mv AT omersecil lowcostpredictorsforliverfunctionandclinicaloutcomesaftersustainedvirologicalresponseinpatientswithhcvrelatedcirrhosisandthrombocytopenia
AT iftimeadrian lowcostpredictorsforliverfunctionandclinicaloutcomesaftersustainedvirologicalresponseinpatientswithhcvrelatedcirrhosisandthrombocytopenia
AT constantinescuileana lowcostpredictorsforliverfunctionandclinicaloutcomesaftersustainedvirologicalresponseinpatientswithhcvrelatedcirrhosisandthrombocytopenia
AT dinaion lowcostpredictorsforliverfunctionandclinicaloutcomesaftersustainedvirologicalresponseinpatientswithhcvrelatedcirrhosisandthrombocytopenia